Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is

Simply Wall StJul 19 09:21 ET

Hong Kong stocks anomaly | Zai Lab (09688) rose more than 3% again. Recently, it announced that its Egamod subcutaneous injection was approved domestically in collaboration with Argenx.

Zai Lab (09688) rose more than 3% again. As of press time, it rose 3.50% to HKD 14.78, with a turnover of HKD 9.3122 million.

Zhitong FinanceJul 17 21:44 ET

Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading

Asian equities traded in the US as American depositary receipts were trending modestly higher Tuesday morning, rising 0.30% to 2,037.69 on the S&P Asia 50 ADR Index.From North Asia, the gainers were

MT NewswiresJul 16 10:41 ET

HKEX News | Zai Lab (09688) rose over 4% in the afternoon, as Edaravone Injection was approved domestically for the treatment of generalized myasthenia gravis.

Zai Lab (09688) rose more than 4% in the afternoon and at the time of publication, it rose 3.64%, at HKD 14.24, with a turnover of HKD 29.885 million.

Zhitong FinanceJul 16 01:35 ET

Express News | Zai Lab And Argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China

BenzingaJul 16 01:13 ET

Zai Lab-Supported Study Published in Cell Provides New Insights With Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy

Manuscript represents the first publication from China's gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified

BusinesswireJul 15 14:53 ET